Autologous tumor lysate/Bacillus Calmette-Guérin immunotherapy as an adjuvant to conventional breast cancer therapy

J Convit, H Montesinos, H Oviedo, G Romero, B Maccarone, E Essenfeld, A Convit, L E Palacios, J Convit, H Montesinos, H Oviedo, G Romero, B Maccarone, E Essenfeld, A Convit, L E Palacios

Abstract

Introduction: Autologous tumor cell vaccines rely on the concept of preserving an individual's own tumorigenic makeup, expressing its unique set of tumor-associated antigens as well as antigenic elements from the surrounding stroma. These autologous tumor characteristics are usually presented with an immune adjuvant in the hopes of enhancing an immune response.

Methods: The autologous vaccine we used was composed of tumor cells combined with BCG and formalin. Animal safety and toxicity were evaluated using mice tumors for the immunotherapy. A small number of patients with advanced stage breast cancer were recruited for an uncontrolled study, using the vaccine solely or combined with chemotherapy/radiotherapy.

Results: The immunotherapy had shown to be safe in mice and humans. Upon a 5-year follow-up, the survival rate was 60 % for the combined treatment.

Conclusions: The data suggest that the combined treatment could be a feasible and safe therapeutic strategy. However, further controlled studies should be conducted.

Keywords: Autologous; BCG; Breast cancer; Immunotherapy; Vaccine.

Figures

Fig. 1
Fig. 1
Estimated survival rates. The survival rate upon a 5-year period was plotted for the immunotherapy only (IT) group (inverted filled triangle) and the combined treated (CT/RT/IT) group (filled square), as well as for the overall survival across all subjects (filled circle). The calculated 5-year survival is indicated for each plot

References

    1. Liu Y, Hou G, Zhang X, Liu JJ, Zhang S, Zhang J. A pilot randomized clinical study of the additive treatment effect of photodynamic therapy in breast cancer patients with chest wall recurrence. J Breast Cancer. 2014;17(2):161–166. doi: 10.4048/jbc.2014.17.2.161.
    1. Lee MC, Jagsi R. Postmastectomy radiation therapy: indications and controversies. Surg Clin North Am. 2007;87(2):511–526. doi: 10.1016/j.suc.2007.01.011.
    1. May M, Brookman-May S, Hoschke B, Gilfrich C, Kendel F, Baxmann S, et al. Ten-year survival analysis for renal carcinoma patients treated with an autologous tumour lysate vaccine in an adjuvant setting. Cancer Immunol Immunother. 2010;59(5):687–695. doi: 10.1007/s00262-009-0784-6.
    1. Standish LJ, Sweet ES, Novack J, Wenner CA, Bridge C, Nelson A, et al. Breast cancer and the immune system. J Soc Integr Oncol. 2008;6(4):158–168.
    1. Reisfeld RA. The tumor microenvironment: a target for combination therapy of breast cancer. Crit Rev Oncog. 2013;18(1–2):115–133. doi: 10.1615/CritRevOncog.v18.i1-2.70.
    1. Hayes DF, Paoletti C. Circulating tumour cells: insights into tumour heterogeneity. J Intern Med. 2013;274(2):137–143. doi: 10.1111/joim.12047.
    1. Junttila MR, de Sauvage FJ. Influence of tumour micro-environment heterogeneity on therapeutic response. Nature. 2013;501(7467):346–354. doi: 10.1038/nature12626.
    1. Srivatsan S, Patel JM, Bozeman EN, Imasuen IE, He S, Daniels D, et al. Allogeneic tumor cell vaccines: the promise and limitations in clinical trials. Hum Vaccines Immunother. 2014;10(1):52–63. doi: 10.4161/hv.26568.
    1. Dols A, Meijer SL, Smith JW, 2nd, Fox BA, Urba WJ. Allogeneic breast cancer cell vaccines. Clin Breast Cancer. 2003;3(4):S173–S180. doi: 10.3816/CBC.2003.s.008.
    1. Jocham D, Richter A, HoVmann L, Iwig K, Fahlenkamp D, Zakrzewski G, et al. Adjuvant autologous renal tumour cell vaccine and risk of tumour progression in patients with renal cell carcinoma after radical nephrectomy phase III randomized controlled trial. Lancet. 2004;363(9409):594–599. doi: 10.1016/S0140-6736(04)15590-6.
    1. Han RF, Pan JG. Can intravesical bacillus Calmette–Guérin reduce recurrence in patients with superficial bladder cancer? A meta-analysis of randomized trials. Urology. 2006;67(6):1216–1223. doi: 10.1016/j.urology.2005.12.014.
    1. Cáceres-Dittmar G, Tapia FJ, Sanchez MA, Yamamura M, Uyemura K, Modlin RL, et al. Determination of the cytokine profile in American cutaneous leishmaniasis using the polymerase chain reaction. Clin Exp Immunol. 1993;91(3):500–505. doi: 10.1111/j.1365-2249.1993.tb05931.x.
    1. Gross A, Weiss E, Tapia FJ, Aranzazu N, Gallinoto ME, Convit J. Leukocyte subsets in the granulomatous response produced after inoculation with Mycobacterium leprae-BCG in lepromatous patients. Am J Trop Med Hyg. 1988;38(3):608–612.
    1. Convit J, Pinardi ME, Rodríguez Ochoa G, Ulrich M, Avila JL, Goihman M. Elimination of Mycobacterium leprae subsequent to local in vivo activation of macrophages in lepromatous leprosy by other mycobacteria. Clin Exp Immunol. 1974;17(2):261–265.
    1. Convit J, Aranzazu N, Pinardi ME, Ulrich M. Immunological changes observed in indeterminate and lepromatous leprosy patients and Mitsuda-negative contacts after the inoculation of a mixture of Mycobacterium leprae and BCG. Clin Exp Immunol. 1979;36(2):214–220.
    1. Convit J, Ulrich M, Aranzazu N, Castellanos PL, Pinardi ME, Reyes O. The development of a vaccination model using two microorganisms and its application in leprosy and leishmaniasis. Lepr Rev. 1986;57(2):263–273.
    1. Convit J, Ulrich M. Desarrollo de una autovacuna + BCG y su posible uso en el tratamiento del cáncer. Gac Méd. 2006;114(4):300–304.
    1. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin. 2005;55(2):74–108. doi: 10.3322/canjclin.55.2.74.
    1. Schirrmacher V, Fournier P, Schlag P. Autologous tumor cell vaccines for post-operative active-specific immunotherapy of colorectal carcinoma: long-term patient survival and mechanism of function. Expert Rev Vaccines. 2014;13(1):117–130. doi: 10.1586/14760584.2014.854169.
    1. Couzin-Frankel J. Breakthrough of the year 2013. Cancer Immunotherapy. Science. 2013;342(6165):1432–1433. doi: 10.1126/science.342.6165.1432.
    1. Keenan BP, Jaffee EM. Whole cell vaccines-past progress and future strategies. Semin Oncol. 2012;39(3):276–286. doi: 10.1053/j.seminoncol.2012.02.007.
    1. Wiseman CL. Inflammatory breast cancer: 10-year follow-up of a trial of surgery, chemotherapy, and allogeneic tumor cell/BCG immunotherapy. Cancer Investig. 1995;13(3):267–271. doi: 10.3109/07357909509094460.
    1. Holmberg LA, Sandmaier B. Vaccination as a treatment for breast or ovarian cancer. Expert Rev Vaccines. 2004;3(3):269–277. doi: 10.1586/14760584.3.3.269.
    1. Hanna MG., Jr Immunotherapy with autologous tumor cell vaccines for treatment of occult disease in early stage colon cancer. Hum Vaccines Immunother. 2012;8(8):1156–1160. doi: 10.4161/hv.20740.

Source: PubMed

Sponsorer og samarbeidspartnere

Medisinsk tilstand

Legemiddelintervensjoner

3
Abonnere